Scholar Rock (NASDAQ:SRRK) CFO Vikas Sinha Sells 16,755 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) CFO Vikas Sinha sold 16,755 shares of the stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $42.70, for a total value of $715,438.50. Following the completion of the transaction, the chief financial officer owned 583,245 shares in the company, valued at $24,904,561.50. The trade was a 2.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Scholar Rock Trading Up 2.1%

Shares of SRRK stock traded up $0.95 on Thursday, reaching $46.53. 988,383 shares of the stock were exchanged, compared to its average volume of 911,044. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.30 and a quick ratio of 6.30. Scholar Rock Holding Corporation has a one year low of $22.71 and a one year high of $48.28. The stock has a market cap of $4.75 billion, a PE ratio of -14.77 and a beta of 0.63. The stock has a 50 day moving average price of $42.02 and a 200 day moving average price of $36.87.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period in the previous year, the business posted ($0.66) earnings per share. Equities research analysts forecast that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP increased its holdings in shares of Scholar Rock by 124.5% in the third quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after acquiring an additional 2,521,022 shares in the last quarter. Holocene Advisors LP acquired a new position in shares of Scholar Rock in the 3rd quarter valued at approximately $91,670,000. Norges Bank bought a new stake in Scholar Rock during the 2nd quarter worth approximately $41,628,000. Balyasny Asset Management L.P. acquired a new stake in Scholar Rock during the 2nd quarter worth approximately $33,062,000. Finally, UBS Group AG lifted its stake in Scholar Rock by 233.8% in the third quarter. UBS Group AG now owns 1,131,787 shares of the company’s stock valued at $42,148,000 after buying an additional 792,760 shares in the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently weighed in on SRRK shares. UBS Group assumed coverage on Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price target on the stock. Truist Financial dropped their price objective on Scholar Rock from $54.00 to $44.00 and set a “buy” rating for the company in a report on Monday, October 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. BMO Capital Markets restated an “outperform” rating and set a $50.00 target price on shares of Scholar Rock in a research report on Friday, November 14th. Finally, HC Wainwright lowered their price target on Scholar Rock from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Tuesday, September 23rd. Four analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Scholar Rock has a consensus rating of “Buy” and a consensus price target of $50.14.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).